StudyFinder

Search Results Within Category "Dermatology (Skin, Hair & Nails)"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
13 Study Matches

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

We are studying a new drug, INCB054707, used to treat people who have hidradenitis suppurativa which is a chronic skin condition characterized by lumps or boils in places such as the armpits or groin. The skin lesions develop because of inflammation of the follicle. We are studying two doses of the drug and we will compare the effectiveness and side effects that occur. We will also have a group that receives an inactive medication (placebo). After the first 12 weeks of taking the drug or placebo, all participants will receive the active drug. The study will last for about 62 weeks.

Noah Goldfarb
18 years and over
This study is NOT accepting healthy volunteers
SITE00001790
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• moderate to severe H.S. for at least 3 months
Exclusion Criteria:

• mild H.S.
• women who are pregnant (or who are considering pregnancy) or breastfeeding
Dermatology (Skin, Hair & Nails), Rare Diseases
Hidradenitis Suppurativa( HS)
I'm interested
Share via email

Neptunia A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care

This research is studying enpatoran (M5049) as a possible treatment for dermatomyositis (DM) and polymyositis (PM). The study will last for approximately 31 weeks (upto 9 study visits) and an additional optional 24 weeks (upto 5 study visits) if you agree to participate in the extension period for a total of up to 14 months (55 weeks). It will include approximately up to 3 telephone calls from the study center. The main activities in the study include: providing consent to participate, performing tests to check your health throughout the study (such as physical exams, electrocardiogram (ECG) testing, collection of urine and blood draws for laboratory testing), study drug dosing and recording relevant information in the study diary, and performing tests, completing questionnaires and assess signs and symptoms of your condition. This is a Phase 2a study. and it is anticipated that approximately 40 people will participate in this study.

David Pearson
18 years and over
This study is NOT accepting healthy volunteers
SITE00001761
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults with primarily diagnosed with Dermatomyositis (DM) or Polymyositis (PM)
Exclusion Criteria:
Diagnosis of myositis within 3 years of cancer
Dermatology (Skin, Hair & Nails)
Dermatomyositis (DM), Polymyositis (PM)
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and;Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute&Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care

The main purpose of this research study is to see whether enpatoran works for people with SLE or CLE, and to find out more about how safe and well tolerated it is. Participation in this research study will last for approximately 33 weeks (this includes a 24-week study drug period).

David Pearson
18 years and over
This study is NOT accepting healthy volunteers
SITE00001757
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• adults 18-75 years of age
• disease duration at least 6 months of either active discoid or subacute cutaneous lupus OR active systemic lupus
• on stable dose(s) of standard-of-care therapies for lupus
• willing to use contraception for the study period
Exclusion Criteria:

• Drug-induced lupus, within 3 months of induction therapy for lupus nephritis, or active CNS lupus
• history of epilepsy, significant cardiovascular events including arrhythmia, solid organ transplantation, or malignancy
• active infection including HIV, HBV, HCV, or tuberculosis
• there are specified wait times for people taking certain prior drugs (study staff will review)
Arthritis & Rheumatic Diseases, Dermatology (Skin, Hair & Nails), Rare Diseases
lupus, discoid, SLE, CLE, DLE, SCLE, WILLOW, enpatoran, M5049, Merck, EMD Serono, Pearson
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years& Less than 18 Years of Age with Alopecia Areata

We are conducting a research study for children ages 6-17 with patchy Alopecia Areata (AA). The purpose of this research study is to learn more about the safety, tolerability and efficacy of an investigational drug called Baricitinib. This study will compare the investigational drug to a placebo (inactive substance) to see how well the investigational drug works.

Maria Hordinsky
Up to 18 years old
This study is NOT accepting healthy volunteers
SITE00001967
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• children 6 to 18 years old
• at or above the 5th percentile of weight for age
• diagnosis of Alopecia Areata (AA) for at least 1 year
• current AA episode of at least 6 months duration with hair loss encompassing 50% or more of the scalp
• history of trial and failure with at least 1 available treatment
• history of psychological counseling related to AA
Exclusion Criteria:

• primarily diffuse type of AA (characterized by diffuse hair shedding)
• currently experiencing other forms of alopecia including, but not limited to: trichotillomania, TE, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis)
Dermatology (Skin, Hair & Nails)
AA, Alopecia Areata, hair loss
I'm interested
Share via email

A 6-Month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone (Cortexolone 17A-Propionate) Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-Month Single-Blind Treatment with Clascoterone or Vehicle BID Solution. (SCALP 1) (SCALP1)

We are studying a new topical drug, Clascoternone, to treat adult males who have male pattern baldness. Participants randomly (by chance) receive the drug or an inactive solution that is applied to the area of hair loss twice a day for six months. We will compare the effectiveness and side effects of the two groups. Men who have regrowth of hair may also participate in a second six-month treatment to look at the long-term effectiveness of the drug.

Maria Hordinsky
18 years and over
This study is NOT accepting healthy volunteers
SITE00002038
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• men who are 18 or older
• have mild to moderate Androgenic Alopecia (AGA) in temple and top region of the scalp
• willing to maintain the same hairstyle, hair length and hair color throughout the study
• agree to continue shampoo frequency and other general hair care products and regimen for the entire study
• agree to maintain same dietary and supplement pattern
Exclusion Criteria:

• any dermatological disorders at the temple or the top of the scalp
• current or recent history (within 6 months) of hair weaves, non-breathable wigs, or hair bonding -scalp hair transplants at any time
• see link to clinicaltrials.gov for additional exclusion criteria (study staff will review)
Dermatology (Skin, Hair & Nails)
Clinics and Surgery Center (CSC), Alopecia, Androgenetic Alopecia, Male Alopecia, AGA
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared with its Placebo in Male or Female AlopeciaAreata Participants Aged 18 Years and Older with 50% or Greater Scalp Hair Loss (FAST-AA)

The main purpose of the study is to see whether farudodstat, taken orally for 12 weeks, can help people with alopecia areata and to find out if farudodstat is safe and tolerable when compared to placebo. The placebo is a pill that looks like farudodstat tablet but has no drug or other active ingredient in it.

Maria Hordinsky
18 years and over
This study is NOT accepting healthy volunteers
SITE00001917
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• at least 18 years old
• weight at least 40 kg (88 lbs)
• severe or very severe Alopecia Areata (AA)
• contact study staff for additional criteria for AA
Exclusion Criteria:

• history of androgenic alopecia or female pattern hair loss prior to AA or other types of hair loss
• history or presence of hair transplants
• other scalp disease that may impact AA assessment or require topical treatment (including, but not limited to scalp psoriasis, seborrheic dermatitis, actinic keratosis)
Dermatology (Skin, Hair & Nails)
Alopecia Areata, Hair loss
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis (VALOR)

In this study, brepocitinib will be compared to a placebo. Brepocitinib is an investigational medicine because it has not yet been approved by any regulatory agency for use. Researchers will compare the results of taking the placebo to the results of taking the study medicine to see if there are any differences. This medicine may be helpful for your disease, but we do not have any information about this yet. 67% of participants will receive brepocitinib and 33% will receive the placebo which will be decided randomly by chance. Participation will last for up to 64 weeks (15 months). Visits will be scheduled about every 4 to 6 weeks.

David Pearson
18 years and over
This study is NOT accepting healthy volunteers
SITE00001688
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of dermatomyositis
• active muscle and skin disease or being treated with medications
• age 18-75
• weight at least 40 kg, less than 130 kg and a BMI less than 40 kg/m2
Exclusion Criteria:

• history of cancer in past 5 years
• dermatomyositis with irreversible muscle involvement
• active or recent infections
Arthritis & Rheumatic Diseases, Dermatology (Skin, Hair & Nails)
Clinics and Surgery Center (CSC), dermatomyositis
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 1/2A, (Part B, participant-, investigator-, and sponsor-blind) study; to investigate the safety, pharmacokinetics, and efficacy (Part B only) of UCB1381 in study participants with moderate to severe atopic dermatitis;(Part B)

This is an early study of a new drug called UCB1381. In the first part of the study, we are looking at increasing doses of the drug when compared to an inactive drug (placebo) when given to healthy participants. In the second part, we will look at the safety and effectiveness of one dose of UCB1381 compared to an inactive drug (placebo) when given to people who have moderate to severe Atopic Dermatitis.

Paul Bigliardi
18 years and over
This study is NOT accepting healthy volunteers
SITE00001885
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18-65 years of age
• moderate to severe itch
Exclusion Criteria:

• diabetes not well controlled with diet
• history of Crohns disease or Colitis
Dermatology (Skin, Hair & Nails)
Atopic Dermatitis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis (PACIFIC)

The purpose of this study is to find out the safety and tolerability (the degree to which side effects affect a participant’s willingness to continue taking study drug) of the study drug EP547 in patients with itch associated with cholestatic liver disease and to determine the amount of EP547 in the blood after dosing. EP547 is an experimental drug that is not approved by the Food and Drug Administration (FDA) for the treatment of itch associated with liver disease or of any other conditions. This study will have 9 study visits which includes a screening period of up to 4 weeks long, a 12-week treatment period, and a follow-up visit 2 weeks after stopping study treatment.

Mary Thomson
18 years and over
This study is NOT accepting healthy volunteers
STUDY00016629
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosed with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC
• consistent moderate to severe pruritus (itching)
Exclusion Criteria:

• prior or planned liver transplantation
• liver cirrhosis
• significant small bowel resection or short bowel syndrome
Dermatology (Skin, Hair & Nails), Digestive & Liver Health
Clinics and Surgery Center (CSC), Itching, Pruritus
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata

This study is being done to evaluate the safety and tolerability of twice daily application of the study drug, ARQ-255 topical suspension 3% people with alopecia areata. There are 2 study drugs in this study: ARQ-255 topical suspension 3% and vehicle (placebo). Participants will be randomized (like drawing straws) to either ARQ-255 topical suspension 3% or vehicle to be applied twice daily for 12 weeks. A vehicle is a study treatment that looks like the test drug and is made from the same base products used to make ARQ-255 topical suspension 3%, but it does not contain any active study ingredients.

Maria Hordinsky
18 years and over
This study is NOT accepting healthy volunteers
SITE00001818
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• 18 to 70 years of age
• have alopecia areata
• able to apply topical study medication
Exclusion Criteria:

• alopecia totalis
• alopecia universalis
Dermatology (Skin, Hair & Nails)
alopecia areata
I'm interested
Share via email

Use of Continuous Wave Doppler to assess Vascular Malformations in Pediatric Dermatology

The aim of our study is to look at blood flow in various tumors and irregularities located in blood vessels using a handheld continuous wave doppler. Correct and efficient diagnosis of vascular anomalies (outside of what is expected to happen in blood vessels) in pediatric patients will help determine a treatment plan. Blood flow in vascular anomalies has not been well described in the past.

Sheilagh Maguiness
Not specified
This study is NOT accepting healthy volunteers
STUDY00012200
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• less than 21 years old
• have a vascular anomaly such as Arteriovenous malformations (AVM), Capillary malformations (CM), Venous malformations (VM), Lymphatic malformations (LM), Pyogenic granuloma (PG), Infantile hemangioma (IH), or Congenital hemangioma (CH)
• being treated at University of MN pediatric dermatology outpatient clinic or the multidisciplinary vascular anomalies clinic
Exclusion Criteria:

• history of any prior surgical, radiologic, medications for treatment (including oral or topical beta blocking agents)
Dermatology (Skin, Hair & Nails)
Vascular Anomalies
I'm interested
Share via email

Cleansing device for the treatment of scalp and hair conditions

The objective of this study is to evaluate an improvement of scalp health after the use of an investigational off-label WaterPik and brush device aimed to massage and cleanse the scalp.

Ronda Farah
18 years and over
This study is also accepting healthy volunteers
STUDY00012927
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• one of the following scalp conditions based on clinical opinion of a board-certified dermatologist: healthy scalp, dandruff, seborrheic dermatitis, or hair loss disease
• willing to defer pregnancy and use two contraceptive methods for the period of the study treatment
Exclusion Criteria:

• non-English speaking
• pregnant
• clinical condition that, in the opinion of the site investigator, would interfere with adherence to study requirements
Dermatology (Skin, Hair & Nails)
Hair Loss, Scalp disease, Seborrheic Dermatitis, Dandruff
I'm interested
Share via email
See this study on ClinicalTrials.gov

An Open Label Study to Evaluate DPCP Ointment for the Treatment of Alopecia Areata

The purpose of the study is two-fold. First, we will see whether treating alopecia areata with a ointment containing DPCP is safe and causes hair to regrow. Second, we will take blood and scalp biopsy samples and analyze them for biomarkers. The biomarkers in this study are molecules related to DNA that tell us whether certain genes are turned on or off. Those markers may help us predict whether or not patients respond to this type of treatment. The testing for biomarkers will also help us to better understand what causes alopecia areata. This study requires you to make forty-two (42) visits to the study site over a course of approximately four (4) months.

Maria Hordinsky
18 years and over
This study is NOT accepting healthy volunteers
1407M52002
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• diagnosis of extensive alopecia areata
• women of childbearing age must agree to use an acceptable, highly effective method of birth control to prevent pregnancy
Exclusion Criteria:

• women who are pregnant or breast feeding
• current controlled or uncontrolled infection of any type
• systemic therapy for cancer within the past five years except for adequately treated Squamous Cell Carcinoma (SCC) or Basal Cell Carcinoma (BCC) of the skin
• additional medical conditions, treatments for alopecia areata, or mental health diagnosis (study staff will review)
Dermatology (Skin, Hair & Nails)
Alopecia Areata
I'm interested
Share via email
See this study on ClinicalTrials.gov